|
|
 | | | |
- close
- close
- close
- close
Intercell (HAM:IJE) |
QUOTE AND NEWS
FierceBiotech
Jul 18
Comment
Novartis might not be the knight in shining armor that some perhaps hoped for at struggling vaccine firm Intercell, which has been open to a buyout after a series of development setbacks during the past year. Yet now there's talk that Novartis has...
Wall Street Journal
Jun 8
Comment
Merck and Intercell terminated a clinical trial of a vaccine for Staphylococcus aureus infection over safety concerns.
StreetInsider.com
Jun 8
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Merck+%28MRK%29%2C+Intercell+Report+Termination+of+V710+Phase+IIIII+Per+DMC+Request/6567410.html for the full story.
FiercePharma
May 31
Comment
Austria's Intercell has recalled a batch of its only marketed product, a vaccine against Japanese encephalitis, because of possible potency problems, Reuters reports. The shot, Ixiaro, has been sold since 2009, and the company says it sees no...
FierceBiotech
May 5
Comment
After stumbling badly in the clinic, Austria's Intercell announced that CEO Gerd Zettlmeissl has abruptly resigned and been replaced by COO Thomas Lingelbach. Late last year shares of Intercell AG, the last of the independent vaccine makers,...
MedPage Today
Apr 12
Comment
(MedPage Today) -- A phase II/III trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus infection, has been stopped, according to a brief statement from Merck and Intercell AG.
FierceBiotech
Apr 11
Comment
Austria's Intercell ($ICLL) saw its stock take another nasty dive after a safety panel warned investigators against recruiting more patients for a Phase II/III clinical trial of an experimental vaccine. V710--which is partnered with Merck--is...
MarketWatch
Apr 11
Comment
Merck & Co. and Intercell AG said Monday that the data-monitoring committee for their Phase II-III clinical trial of V710, a vaccine in testing to prevent staphylococcus aureus infection, urged them to suspend enrolling patients. Merck, the...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
